menu
    • menu
    [{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"NVD-003","moa":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"NVD-001","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"NVD-001","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"NVD-X3","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Novadip Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Science Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Novadip Biosciences \/ Science Ventures"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"NVD-003","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NVD-003","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"NVDX3","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NVD-003","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Novadip Biosciences

    Menu

    Novadip Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Results from Novadip Phase 1b/2a Trial Reveal 88% Efficacy

                            Details : NVD-003 is an autologous cell-based therapy which is is made from a patient's own adipose stem cells. It is being evaluated for the treatment of congenital pseudarthrosis of tibia.

                            Product Name : NVD-003

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 28, 2025

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVDX3

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novadip Achieves Milestones for NVDX3 IND in Cervical Spine Fusion Study

                            Details : NVDX3 is in clinical development for common orthopedic conditions. Currently, it is being evaluated in the early-stage clinical trial studies for cervical spine fusion.

                            Product Name : NVDX3

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 20, 2024

                            Lead Product(s) : NVDX3

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoe...

                            Details : NVD-003 is an autologous therapy derived from adipose stem cells, which reverses severe bone deterioration and to achieve accelerated ossification, is being investigated as a single treatment to save limbs and restore mobility​ in patients with CPT.

                            Product Name : NVD-003

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 17, 2023

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone N...

                            Details : NVD-003, an autologous tissue engineered product generated from the patients’ own adipose stem cells, was applied in nine patients with bone non-union of the lower limb who had previously undergone several surgical procedures.

                            Product Name : NVD-003

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-X3

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Science Ventures

                            Deal Size : $88.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

                            Details : NVD-X3 is an allogeneic therapeutic that can provide accelerated, durable bone union in spinal fusion procedures and non-healing fractures, and NVD-003 is an autologous bone engraftment product designed to provide a single treatment cure for critical siz...

                            Product Name : NVD-X3

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 03, 2022

                            Lead Product(s) : NVD-X3

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Science Ventures

                            Deal Size : $88.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novadip Biosciences Reports Positive Data From phase I Study of NVD-001 For Spinal Fusion

                            Details : NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform. Study met its primary endpoint. NVD-001 showed a favorable safety profile over a two-ye...

                            Product Name : NVD-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 15, 2021

                            Lead Product(s) : NVD-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-001

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novadip Biosciences Reports pOsitive Data from Phase I Study of NVD-001 for Spinal Fusion

                            Details : NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform.

                            Product Name : NVD-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 15, 2021

                            Lead Product(s) : NVD-001

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003

                            Details : NVD-003 is a novel autologous cell-based osteogenic (bone healing) product that has been generated from Novadip’s proprietary tissue regeneration platform. Made from adipose stem cells, NVD-003 has a 3-dimensional structure and works by promoting bone ...

                            Product Name : NVD-003

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 04, 2021

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth